Xie Zhu

Efficacy and safety of immune checkpoint inhibitors combined with recombinant human endostatin and chemotherapy as the first-line treatment of advanced non-small-cell lung cancer.

K. Shang, Pei Zhong, Li Chen, 2023, Future oncology.

Immunotherapy combined with rh-endostatin improved clinical outcomes over immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC

Pei Zhong, Li Chen, Z. Lu, 2023, Frontiers in Oncology.

Anlotinib plus tislelizumab for recurrent metastatic pancreas ductal adenocarcinoma with germline BRCA2 mutation: A case report

Xinjing Ding, Sujuan Peng, Xie Zhu, 2024, Experimental and therapeutic medicine.